BRUNS INGMAR (Chief Medical Officer) purchased 120.3% of their position (20K shares) of ZENTALIS PHARMACEUTICALS, INC. on the open market
Open‑market purchase worth $45.7K — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 2/12/2025ACC: 0001725160-25-000047
Officer· Chief Medical Officer
Since Feb 2026
+20K
Net shares
Net buyer
$45.7K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
20K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+20K
Price / share
$2.28
Trade value
$45.66K
% of position
120.3%
2/6/2025
16.63K→36.63K
Total
Net shares
+20K
Net value
$45.66K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/6/2025 | P · Purchase | +20K | $2.28 | $45.66K | 120.3% | 16.63K | 36.63K |
| Total | +20K | $45.66K | ||||||
Derivative Transactions0
No derivative transactions reported